Related Experiment Video
Updated: Feb 5, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental
Natalia Carrillo-López1, Sara Panizo1, Cristina Alonso-Montes1
1Bone and Mineral Research Unit, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), REDinREN-ISCIII, Oviedo, Spain.
Insights
In chronic kidney disease (CKD), high parathyroid hormone (PTH) worsens vascular calcification and bone loss. Lowering PTH in hyperphosphatemic rats reduced vascular calcium and bone loss by inhibiting osteogenic differentiation.
Area of Science:
- Nephrology
- Endocrinology
- Vascular Biology
Background:
- Chronic kidney disease (CKD) is associated with elevated serum phosphate and parathyroid hormone (PTH).
- These elevations contribute to vascular calcification (VC) and bone loss.
- Distinguishing the specific roles of high phosphorus (HP) and PTH in these complications is crucial.
Purpose of the Study:
- To investigate the individual contributions of high phosphorus (HP) and elevated parathyroid hormone (PTH) to vascular calcification (VC) and bone loss in a rat model of CKD.
- To elucidate the molecular mechanisms underlying these contributions.
Main Methods:
- Nephrectomized rats were fed a high phosphorus (HP) diet.
- Rats underwent either sham operation or parathyroidectomy with PTH 1-34 supplementation to normalize serum PTH levels.
- Vascular and bone tissues were analyzed for calcification and resorption markers.
- Vascular smooth muscle cells (VSMCs) were studied in vitro.
Main Results:
- Parathyroidectomy with PTH 1-34 supplementation significantly reduced aortic calcium by 80% in uraemic rats, attenuating osteogenic differentiation and increasing sclerostin.
- Bone loss was prevented by attenuating bone resorption and increasing Wnt inhibitors.
- Serum calcitriol decreased by 70% despite reduced FGF23, challenging FGF23's role in calcitriol regulation.
- In vitro, high PTH enhanced VSMC calcification, while low PTH attenuated it via PTH1R signaling.
Conclusions:
- In hyperphosphatemic CKD, inadequate suppression of high PTH exacerbates HP-induced osteogenic VSMC differentiation.
- High PTH also reduces vascular sclerostin levels, a key inhibitor of calcification.
- These findings highlight the detrimental role of excessive PTH in CKD-related vascular and bone pathology.
Background:
In chronic kidney disease (CKD), increases in serum phosphate and parathyroid hormone (PTH) aggravate vascular calcification (VC) and bone loss. This study was designed to discriminate high phosphorus (HP) and PTH contribution to VC and bone loss.
Methods:
Nephrectomized rats fed a HP diet underwent either sham operation or parathyroidectomy and PTH 1-34 supplementation to normalize serum PTH.
Results:
In uraemic rats fed a HP diet, parathyroidectomy with serum PTH 1-34 supplementation resulted in (i) reduced aortic calcium (80%) by attenuating osteogenic differentiation (higher α-actin; reduced Runx2 and BMP2) and increasing the Wnt inhibitor Sclerostin, despite a similar degree of hyperphosphataemia, renal damage and serum Klotho; (ii) prevention of bone loss mostly by attenuating bone resorption and increases in Wnt inhibitors; and (iii) a 70% decrease in serum calcitriol levels despite significantly reduced serum Fgf23, calcium and renal 24-hydroxylase, which questions that Fgf23 is the main regulator of renal calcitriol production. Significantly, when vascular smooth muscle cells (VSMCs) were exposed exclusively to high phosphate and calcium, high PTH enhanced while low PTH attenuated calcium deposition through parathyroid hormone 1 receptor (PTH1R) signalling.
Conclusions:
In hyperphosphataemic CKD, a defective suppression of high PTH exacerbates HP-mediated osteogenic VSMC differentiation and reduces vascular levels of anti-calcifying sclerostin.
Related Concept Videos
Hormonal Regulation
Hormonal Regulation
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management

